X0306 4 2020-12-02 1 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001375378 Gitman Paul C/O BIOSPECIFICS TECHNOLOGIES CORP. 2 RIGHTER PKWY, DE CORP CENTER II WILMINGTON DE 19803 1 0 0 0 Common Stock, $0.001 par value 2020-12-02 4 D 0 16890 D 1726 D Common Stock, $0.001 par value 2020-12-02 4 D 0 1726 D 0 D Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020 (the "Merger Agreement"), 16,890 shares of common stock were exchanged for a cash payment of $1,494,765.00, representing the product obtained by multiplying the offer price ($88.50) by the number of shares owned by the reporting person. Upon the consummation of the Merger, pursuant to the Merger Agreement, 1,726 outstanding restricted stock units ("RSUs") were cancelled in exchange for a cash payment of $152,751.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the RSUs, by (y) the offer price ($88.50). /s/ Paul Gitman, by Carl A. Valenstein, attorney-in-fact 2020-12-02